Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZYMEWORKS INC.

(ZYME)
  Report
Delayed Nyse  -  04:00 2022-12-06 pm EST
7.030 USD   -7.74%
12/05Zymeworks to Move Stock Listing to Nasdaq
MT
12/05Zymeworks to Transfer Stock Listing to Nasdaq
BU
11/29Zymeworks to Get Upfront Payment From Jazz Pharmaceuticals as Antitrust Period for Zanidatamab License Deal Expires
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zymeworks Presents Early-Stage Results for Prospective Cancer Therapy

09/12/2022 | 05:01pm EST


ę MT Newswires 2022
All news about ZYMEWORKS INC.
12/05Zymeworks to Move Stock Listing to Nasdaq
MT
12/05Zymeworks to Transfer Stock Listing to Nasdaq
BU
11/29Zymeworks to Get Upfront Payment From Jazz Pharmaceuticals as Antitrust Period for Zani..
MT
11/29Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab Lice..
BU
11/29Zymeworks Inc Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab ..
CI
11/22Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Recepto..
AQ
11/22Zymeworks Announces Participation in Upcoming Investor Conference
BU
11/21HC Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Ratin..
MT
11/21Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Recepto..
BU
11/08Transcript : Zymeworks Inc., Q3 2022 Earnings Call, Nov 08, 2022
CI
More news
Analyst Recommendations on ZYMEWORKS INC.
More recommendations
Financials (USD)
Sales 2022 195 M - -
Net income 2022 -50,4 M - -
Net cash 2022 206 M - -
P/E ratio 2022 -5,67x
Yield 2022 -
Capitalization 453 M 453 M -
EV / Sales 2022 1,27x
EV / Sales 2023 3,02x
Nbr of Employees 286
Free-Float 86,5%
Chart ZYMEWORKS INC.
Duration : Period :
Zymeworks Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZYMEWORKS INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 7,03 $
Average target price 12,31 $
Spread / Average Target 75,1%
EPS Revisions
Managers and Directors
Kenneth Harry Galbraith Chairman & Chief Executive Officer
Neil A. Klompas Chief Financial Officer
Christopher Astle Chief Financial Officer & Senior Vice President
Neil Josephson Vice President-Clinical Development
Paul A. Moore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ZYMEWORKS INC.-53.75%488
VERTEX PHARMACEUTICALS46.34%82 493
REGENERON PHARMACEUTICALS, INC.21.36%81 852
BIONTECH SE-35.33%41 250
WUXI APPTEC CO., LTD.-34.04%32 901
GENMAB A/S24.18%30 145